Wolfe Research initiated coverage of Alnylam with a Peer Perform rating. Despite the optimism about HELIOS-B’s success, concerns include there’s limited upside but substantial downside risks due to revenue implications and commercial hurdles in the cardiomyopathy market, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALNY:
- Alnylam price target lowered to $176 from $184 at Morgan Stanley
- Is ALNY a Buy, Before Earnings?
- Chardan lays out top 4 biotech picks for 2024
- Ionis Pharmaceuticals price target raised to $70 from $65 at RBC Capital
- PepGen appoints DeLena as General Counsel, Secretary
Questions or Comments about the article? Write to editor@tipranks.com